- Home
- APP vs GILD Comparison
APP vs GILD Comparison
Compare APP & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APP
- GILD
- Stock Information
- Founded
- APP 2012
- GILD 1987
- Country
- APP United States
- GILD United States
- Employees
- APP N/A
- GILD N/A
- Industry
- APP EDP Services
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- APP Technology
- GILD Health Care
- Exchange
- APP Nasdaq
- GILD Nasdaq
- Market Cap
- APP 129.8B
- GILD 129.9B
- IPO Year
- APP 2021
- GILD 1992
- Fundamental
- Price
- APP $324.70
- GILD $108.50
- Analyst Decision
- APP Buy
- GILD Buy
- Analyst Count
- APP 20
- GILD 25
- Target Price
- APP $409.84
- GILD $110.17
- AVG Volume (30 Days)
- APP 5.7M
- GILD 8.6M
- Earning Date
- APP 08-06-2025
- GILD 08-07-2025
- Dividend Yield
- APP N/A
- GILD 2.91%
- EPS Growth
- APP 232.19
- GILD 1118.07
- EPS
- APP 5.53
- GILD 4.73
- Revenue
- APP $5,135,154,000.00
- GILD $28,735,000,000.00
- Revenue This Year
- APP $22.99
- GILD $1.55
- Revenue Next Year
- APP $20.65
- GILD $3.69
- P/E Ratio
- APP $58.70
- GILD $22.94
- Revenue Growth
- APP 41.63
- GILD 4.68
- 52 Week Low
- APP $60.67
- GILD $64.86
- 52 Week High
- APP $525.15
- GILD $119.96
- Technical
- Relative Strength Index (RSI)
- APP 36.65
- GILD 50.28
- Support Level
- APP $360.75
- GILD $107.19
- Resistance Level
- APP $428.99
- GILD $111.78
- Average True Range (ATR)
- APP 18.56
- GILD 2.85
- MACD
- APP -10.59
- GILD -0.43
- Stochastic Oscillator
- APP 2.81
- GILD 35.89
About APP Applovin Corporation
AppLovin is a vertically integrated advertising technology company that acts as a demand-side platform for advertisers, a supply-side platform for publishers, and an exchange facilitating transactions between the two. About 80% of AppLovin's revenue comes from the DSP, AppDiscovery, while the remainder comes from the SSP, Max, and gaming studios, which develop mobile games. AppLovin announced in February 2025 its plans to divest from the lower-margin gaming studios to focus exclusively on the ad tech platform. AppLovin's primary tool for future growth is Axon 2, which is an ad optimizer operating within the DSP that allows advertisers to place ads according to specified return thresholds.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).